PMID- 19457706
OWN - NLM
STAT- MEDLINE
DCOM- 20110316
LR  - 20141120
IS  - 1879-0593 (Electronic)
IS  - 1368-8375 (Linking)
VI  - 45
IP  - 10
DP  - 2009 Oct
TI  - Using YC-1 to overcome the radioresistance of hypoxic cancer cells.
PG  - 915-9
LID - 10.1016/j.oraloncology.2009.04.005 [doi]
AB  - Targeting hypoxia-inducible factor-1 (HIF-1) active cells in tumors may be an 
      excellent strategy to improve the outcome of radiation therapy. On the basis of 
      the reported role of YC-1 as a HIF-1 inhibitor with anti-cancer activity, we 
      tested the therapeutic efficacy of YC-1 against radioresistance in vitro. The 
      AMC-HN3 cancer cell line, developed from squamous cell carcinoma of the larynx, 
      was cultured under hypoxic conditions or in the presence of cobalt chloride. Both 
      treatments induced nuclear accumulation of HIF-1alpha protein. Cells cultured 
      under normoxic or hypoxic conditions with and without YC-1 treatment were 
      irradiated and analyzed using flow cytometry and clonogenic assays. In the 
      absence of YC-1 treatment, irradiation induced a greater cytotoxic effect in 
      normoxic cells than in cobalt-treated cells. Treatment of cobalt-treated cells 
      with YC-1 effectively inhibited HIF-1alpha expression, and enhanced the 
      sensitivity of cells to radiation, decreasing the surviving fraction to that of 
      normoxic cells. Flow cytometry confirmed these results, showing that the sub-G1 
      fraction was increased in YC-1-treated hypoxic cells after irradiation. Our 
      results suggest that YC-1 treatment may be an effective therapeutic strategy for 
      overcoming the radioresistance of HIF-1alpha-expressing, hypoxic cancer cells.
FAU - Moon, So Young
AU  - Moon SY
AD  - Department of Otolaryngology, Asan Medical Center, University of Ulsan College of 
      Medicine, 388-1, Pungnap-dong, Songpa-gu, Seoul 138-736, Republic of Korea.
FAU - Chang, Hyo Won
AU  - Chang HW
FAU - Roh, Jong-Lyel
AU  - Roh JL
FAU - Kim, Gui Chull
AU  - Kim GC
FAU - Choi, Seung-Ho
AU  - Choi SH
FAU - Lee, Sang-wook
AU  - Lee SW
FAU - Cho, Kyung-Ja
AU  - Cho KJ
FAU - Nam, Soon Yuhl
AU  - Nam SY
FAU - Kim, Sang Yoon
AU  - Kim SY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090519
PL  - England
TA  - Oral Oncol
JT  - Oral oncology
JID - 9709118
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (Indazoles)
RN  - 0 (Radiation-Sensitizing Agents)
RN  - 154453-18-6 (3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole)
SB  - IM
MH  - Carcinoma, Squamous Cell/radiotherapy
MH  - Cell Hypoxia/*drug effects
MH  - Cell Line, Tumor
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/*antagonists & inhibitors
MH  - In Vitro Techniques
MH  - Indazoles/*pharmacology
MH  - Laryngeal Neoplasms/radiotherapy
MH  - Radiation Tolerance/*drug effects
MH  - Radiation-Sensitizing Agents/*pharmacology
MH  - Treatment Outcome
EDAT- 2009/05/22 09:00
MHDA- 2011/03/17 06:00
CRDT- 2009/05/22 09:00
PHST- 2009/03/26 00:00 [received]
PHST- 2009/04/14 00:00 [revised]
PHST- 2009/04/15 00:00 [accepted]
PHST- 2009/05/22 09:00 [entrez]
PHST- 2009/05/22 09:00 [pubmed]
PHST- 2011/03/17 06:00 [medline]
AID - S1368-8375(09)00101-8 [pii]
AID - 10.1016/j.oraloncology.2009.04.005 [doi]
PST - ppublish
SO  - Oral Oncol. 2009 Oct;45(10):915-9. doi: 10.1016/j.oraloncology.2009.04.005. Epub 
      2009 May 19.